secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0000012208-25-000004
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla
--------------------------------------------------------------------------------

- Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.
- Full-year 2024 revenue $2,566.5M vs $2,671.2M; non-GAAP op margin 12.9% vs 14.2%.
- Restructuring plan eliminates ~5% of workforce; expected cost $45-50M, $30-35M charge in Q1 2025.
- Binding offer to acquire all equity of Stilla Technologies (digital PCR); close expected by Q3 2025.
- No deal value disclosed; acquisition subject to regulatory approvals and employee consultation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/0000012208-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000004/bio-20250207.htm
  HTML page:      https://secwatch.observer/filing/0000012208-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer